AEON Biopharma, Inc.

AMEX: AEON · Healthcare · Biotechnology

PublicHQ Newport Beach, CA · OrangeCIK 0001837607Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 13DQ —GM —SS 26

v0.1 · 35/100 weight · pillars only

↑ market scale, filing timeliness · ↓ listing tenure, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$39.2M

Employees

as of 2026-08-22

Market cap

$8.5M

as of 2026-08-22

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$39.2M-$39.2M2025

Operating income-$12.8M-$12.8M2025

Total assets$5.6M$5.6M2025

Liabilities$60.6M$60.6M2025

Equity-$55.0M-$55.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is AEON Biopharma, Inc.’s financial profile?

AEON Biopharma, Inc. earned -$39.2M in FY2025 net income.

Peers · Healthcare

Quince Therapeutics, Inc.——CalciMedica, Inc.——CNS Pharmaceuticals, Inc.——AI Maverick Intel, Inc.——Aprea Therapeutics, Inc.——Univec, Inc.——

Neighbors

Orange →

Edwards Lifesciences Corporation$6.1B86A Chipotle Mexican Grill, Inc.$11.9B77B+Rivian Automotive, Inc.$5.4B37D TTM Technologies, Inc.$2.9B73B American Healthcare REIT, Inc.$2.1B56C The Ensign Group, Inc.$5.0B80B+

Key facts

CEORobert Bancroft

SectorHealthcare

IndustryBiotechnology

HeadquartersNewport Beach, CA

ExchangeAMEX: AEON

Employees8

IPO date2023-07-24

Latest filings

8-K2026-08-12 10-Q2026-08-12 8-K2026-08-03 8-K2026-07-23 8-K2026-07-15 8-K2026-06-17 10-Q2026-05-14 8-K2026-05-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.